For Immediate Release
Chicago, IL – April 1, 2010 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Salesforce.com (CRM), CA Inc. (CA), BMC Software (BMC), Abbott Labs (ABT) and AstraZeneca (AZN).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
CRM Witnesses Customer Growth
Growing enterprise cloud computing company Salesforce.com (CRM) recently declared through a press release that it had substantially increased its customer base in the Asia-Pacific region. During the fiscal year ended January 31, 2010 the company added 1800 new customers in the region, taking the total to 70,000.
This apart, Salesforce is poised to grow strongly in 2010. To enhance its cloud services, the company has recently introduced Spring 10, the company’s 31st-generation service, with advanced features designed for its Sales Cloud 2 platform and Force.com site. This Growing enterprise cloud computing company Salesforce.com recently declared through a press release that it had substantially increased its customer base in the Asia-Pacific region. During the fiscal year ended January 31, 2010 the company added 1800 new customers in the region, taking the total to 70,000.
This apart, Salesforce is poised to grow strongly in 2010. To enhance its cloud services, the company has recently introduced Spring 10, the company’s 31st-generation service, with advanced features designed for its Sales Cloud 2 platform and Force.com site. This advanced cloud computing service is expected to introduce an entirely new user interface for Salesforce.com.
This apart, the company is making strategic alliances with different IT majors like CA Inc. (CA) and BMC Software (BMC). In association with CA, the company has launched CA Agile Planner on the Force.com site, which is mainly targeted at small businesses and enterprises alike. This innovative product will result in reduced time to market.
Regulatory Setback for Abbott
Abbott Labs (ABT) and partner AstraZeneca (AZN) faced a regulatory setback recently when the US Food and Drug Administration (FDA) issued a complete response letter for their experimental drug, Certriad.
Certriad is a fixed-dose, single pill formulation of Abbott’s next-generation triglycerides lowering pill, TriLipix and AstraZeneca’s powerful statin drug, Crestor. This new combination fenofibrate-statin looks to offer the best HDL-raising, LDL/triglyceride-lowering efficacy available.
In its complete response letter, the FDA has asked for additional information. However, the companies refrained from making public any information regarding the FDA’s request.
The delay in Certriad’s approval is a setback for both Abbott and AstraZeneca. Both companies were looking to drive sales of their cardiovascular franchises by launching Certriad.
The companies were initially planning to launch Certriad in the first half of 2010. AstraZeneca is currently co-promoting TriLipix and will co-promote Certriad with Abbott once approved. However, Certriad’s approval could now get delayed by anythingv ranging from 6 months to more than a year, depending on the FDA’s requirements.
The delay could be significant if the FDA asks them to conduct new studies. Abbott and AstraZeneca intend to discuss the requirements with the agency so that they can respond to the complete response letter.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
